Introduction: Immunotherapy is a form of oncologic treatment directed towards enhancing the host immune system against cancer. Immunotherapeutic agents were significantly associated with a higher risk of developing adverse effects in cancer patients. Bevacizumab was significantly associated with higher risk of developing venous thromboembolism, GI perforation such as bleeding and leukopenia in cancer patients. Trastuzumab has led to a significant improvement in the treatment of both advanced and early breast cancer by over expressing HER-2 receptors. It was associated with an important adverse effect, cardiotoxicity. Cetuximab and Panitumumab are monoclonal antibodies targeting the endothelial growth factor receptors (EGFR) currently used for systemic treatment of metastatic colorectal cancer in combination or alone have been reported to be able to induce skin toxicities. Nausea, diarrhea and rash were the most common adverse effects in Pertuzumab alone and Pertuzumab – based therapies. Pertuzumab also increases the risk of clinical heart failure, but not asymptomatic/minimally symptomatic left ventricular systolic dysfunction, in HER2-positive cancer patients. Materials and Methods: An ambispective observational single center study was conducted by collecting details of patients prescribed with Trastuzumab, Bevacizumab Pertuzumab, cetuximab and panitumumab. Retrospective study period of 5 years (2017 November to 2022 November) and Prospective study period of 6 months were conducted (December 2022 to May 2023). Patients of all age groups prescribed with immunotherapeutic agents other than immune checkpoint inhibitors was included and patients who were discharged against medical advice and incomplete data was excluded. Results: Majority of patients in our study were in age groups of 56-65 years with 38.5%. Among 65 patients, 4 of them reported with trastuzumab induced cardiotoxicity and 3 of the patients taking trastuzumab along with pertuzumab also reported with cardiotoxicity. Among 30 patients who were taking bevacizumab, one patient was reported with pneumonitis. We conducted a correlation analysis using chi-square test between study considered drugs and the reported adverse reactions. All of the patients prescribed with Trastuzumab + Pertuzumab were having ADR. Also, majority of the patients prescribed with Bevacizumab were not having ADR. Since the p-value of chi-square test was found to be <0.001 so there exist a significant relation between drugs prescribed and ADR. Conclusion: We assessed the safety profile of immunotherapeutic agents other than immune check point inhibitors in cancer patients. We also correlated the study considered drugs and adverse drug reaction occurrence, there existed a significant correlation.